Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNDROS vs CESAMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dronabinol is a cannabinoid receptor type 1 (CB1) agonist, activating CB1 receptors in the central nervous system to inhibit emetic signals and stimulate appetite. It also has partial agonist activity at cannabinoid receptor type 2 (CB2).
Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.
FDA: Chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics,FDA: Anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS)
Prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics
5 mg/m² orally 1-3 hours before chemotherapy, initially; may increase by 2.5 mg/m² increments as tolerated, maximum 15 mg/m² per dose.
1-2 mg orally twice daily; maximum 6 mg/day.
Terminal elimination half-life is 28–61 hours (mean ~32 hours) in adults; prolonged with high-fat meal. Clinical context: Steady state achieved in 5–6 days.
Terminal elimination half-life is approximately 35 hours (range 25–50 hours) in adults. Due to prolonged half-life and active metabolites, steady-state may take 5–7 days; accumulation occurs with repeated dosing.
Primarily hepatic via cytochrome P450 (CYP) 3A4 and 2C9 isoenzymes; undergoes extensive first-pass metabolism to active and inactive metabolites.
Hepatic, primarily via CYP3A4 and CYP2C9; undergoes first-pass metabolism; multiple metabolites including active 11-hydroxy-nabilone
Approximately 65% of a dose is excreted in feces (primarily as hydroxylated and carboxylated metabolites) and 35% in urine (as metabolites, with <5% unchanged drug).
Primarily hepatic metabolism with biliary excretion. ~65% eliminated in feces as metabolites, ~20% in urine. Less than 1% excreted unchanged.
97–99% bound, primarily to albumin and lipoproteins.
90–95% bound to plasma proteins, primarily albumin.
Vd: 10–80 L/kg (mean ~30 L/kg), indicating extensive tissue distribution.
Approximately 2.5–5.5 L/kg, indicating extensive tissue distribution.
Oral bioavailability: ~10–20% (variable due to extensive first-pass metabolism); increased 2- to 4-fold with a high-fat meal.
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment; insufficient data for severe impairment (e GFR <30 m L/min); use with caution.
No specific dosage adjustment recommended based on GFR; use with caution in severe renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to potential for encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Safety and efficacy not established in pediatric patients; not recommended under 18 years.
Not approved for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment; monitor for increased sensitivity to adverse effects (e.g., dysphoria, hypotension).
Start at 1 mg once daily; titrate slowly due to increased sensitivity to adverse effects.
None
None
Risk of psychiatric adverse reactions, including dysphoria, hallucinations, paranoia, and worsening of pre-existing mental illness,Central nervous system depressant effects and impairment of cognitive function, motor skills, and judgment; caution when driving or operating machinery,Potential for abuse, tolerance, and dependence (Schedule III controlled substance),May increase heart rate and blood pressure; use with caution in patients with cardiovascular disease,Seizures: May lower seizure threshold in patients with epilepsy,Pancreatitis: Cases reported; monitor for symptoms
Central nervous system depression (drowsiness, dizziness, ataxia),Psychiatric effects (euphoria, dysphoria, paranoia, hallucinations),Cognitive and motor impairment (do not drive or operate machinery),Risk of dependence and withdrawal syndrome,Use with caution in patients with history of psychiatric disorders,May increase heart rate and blood pressure
Hypersensitivity to dronabinol or any cannabinoid or sesame oil (capsule contains sesame oil),Concurrent use with disulfiram or metronidazole due to alcohol content in oral solution (however, Syndros is a dronabinol solution; contraindication applies to alcohol-containing formulations – note: Syndros contains alcohol; label contraindicates concurrent use with disulfiram or metronidazole)
Hypersensitivity to nabilone or any cannabinoid,History of seizure disorder,Breastfeeding (excreted in milk)
Food with high fat content may increase dronabinol absorption; take consistently with or without food to avoid variability. Grapefruit and grapefruit juice may increase dronabinol levels; avoid concurrent use.
Take with food or milk to reduce gastrointestinal upset; avoid grapefruit juice as it may alter drug metabolism.
Dronabinol (SYNDROS) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses similar to human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a small increased risk of neural tube defects. Second and third trimester exposure may affect fetal brain development, including potential long-term neurobehavioral effects. Dronabinol crosses the placenta. Use only if potential benefit justifies potential risk to the fetus.
Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may increase risk of congenital malformations. Second and third trimester exposure may affect fetal growth and neurobehavioral development. Potential risks include low birth weight, preterm birth, and neonatal withdrawal symptoms.
Dronabinol is excreted into human milk. The M/P ratio is not specifically determined for dronabinol; however, THC (active component) has an M/P ratio of approximately 0.04 based on limited data. Because of the potential for adverse effects on the nursing infant, such as developmental delay and sedation, breastfeeding is not recommended during SYNDROS therapy. An alternative method of infant feeding should be considered.
Nabilone is excreted into breast milk; a specific M/P ratio is not reported. Due to the high lipid solubility and long half-life, significant infant exposure is expected. Breastfeeding is contraindicated due to potential adverse effects on infant neurodevelopment and cannabinoid receptor activation.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce dronabinol concentrations. However, due to lack of systematic dose-response data and potential fetal risks, routine dose increments are not recommended. The lowest effective dose should be used. If clinical response is suboptimal, consider non-pharmacologic alternatives. Do not exceed maximum recommended doses (20 mg/day).
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced hepatic metabolism) may reduce nabilone serum concentrations, potentially requiring dose adjustments. However, due to lack of safety data, use during pregnancy is not recommended. If deemed essential, the lowest effective dose should be used, and close monitoring for efficacy and toxicity is advised.
Syndros (dronabinol oral solution) is a synthetic delta-9-tetrahydrocannabinol (THC) used for chemotherapy-induced nausea and vomiting (CINV) and anorexia with weight loss in AIDS patients. It has a high first-pass metabolism; avoid use in patients with hepatic impairment. Onset is faster than capsules; dosing must be individualized based on prior cannabis exposure. Monitor for CNS depression and avoid concurrent use with other CNS depressants. Syndros contains alcohol (5% v/v); use cautiously in patients with alcohol intolerance or liver disease. Contraindicated in patients with a history of hypersensitivity to THC or sesame oil (vehicle).
Titrate slowly to reduce risk of syncope and orthostatic hypotension; monitor for dizziness and sedation; may cause euphoria or dysphoria; use with caution in patients with history of psychiatric disorders; taper to discontinue.
Take Syndros 1 to 3 hours before chemotherapy for CINV, or twice daily before lunch and dinner for AIDS-related anorexia.,Avoid driving or operating machinery until you know how Syndros affects you, as it can cause dizziness, drowsiness, and altered judgment.,Do not drink alcohol or take other sedating medications while using Syndros, as this increases the risk of severe sedation.,Report any mood changes, depression, or suicidal thoughts to your healthcare provider immediately.,Store at room temperature (20-25°C) and protect from light; do not freeze.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss use with your doctor; THC can pass into breast milk.,Use a calibrated measuring device for the oral solution (provided with the medication) to ensure accurate dosing.
Avoid driving or operating machinery until you know how this drug affects you.,Get up slowly from sitting or lying down to prevent dizziness or fainting.,Avoid alcohol and other sedatives while taking this medication.,Take exactly as prescribed; do not increase dose without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNDROS vs CESAMET, answered by our medical review team.
SYNDROS is a Cannabinoid that works by Dronabinol is a cannabinoid receptor type 1 (CB1) agonist, activating CB1 receptors in the central nervous system to inhibit emetic signals and stimulate appetite. It also has partial agonist activity at cannabinoid receptor type 2 (CB2).. CESAMET is a Antiemetic (cannabinoid) that works by Nabilone is a synthetic cannabinoid (CB1 receptor agonist) with antiemetic and anxiolytic effects. It binds to central cannabinoid receptors (CB1) in the brain, inhibiting neurotransmitter release and modulating emetic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNDROS and CESAMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNDROS is: 5 mg/m² orally 1-3 hours before chemotherapy, initially; may increase by 2.5 mg/m² increments as tolerated, maximum 15 mg/m² per dose.. The standard adult dose of CESAMET is: 1-2 mg orally twice daily; maximum 6 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNDROS and CESAMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNDROS is classified as Category C. Dronabinol (SYNDROS) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses similar to human therapeutic doses. There are no . CESAMET is classified as Category C. Nabilone (Cesamet) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects including skeletal anomalies at doses 0.2-2 times the maximum recommende. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.